FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.'s Lead Product Candidate in the U.S.

CorMedix is Developing Neutrolin for the Prevention of Catheter Related Bloodstream Infections and Maintenance of Catheter Patency in Hemodialysis, Oncology and Intensive Care

BRIDGEWATER, N.J., Jan. 29, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated the company's lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening.

Published: 29 January 2015
Written by Editor
FDA HC Decision   Up on News  
Read more: CorMedix Inc ( CRMD )

Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R)

MELBOURNE, AUSTRALIA--(Jan 29, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to report that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond.

Published: 29 January 2015
Written by Editor
Nasdaq   Up on News  
Read more: Genetic Technologies Limited ( GENE )

Abiomed Announces Third Quarter Fiscal 2015 Record Revenue of $62.0 Million, up 34% Over the Prior Year

- Impella U.S. Patient Utilization Increases 46% Over the Prior Year

DANVERS, Mass., Jan. 27, 2015 Abiomed Inc ( ABMD ), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2015 revenue of $62.0 million, up 34% compared to revenue of $46.2 million in the same period of fiscal 2014, and a third quarter fiscal 2015 GAAP net income of $12.7 million, or $0.30 per diluted share, compared to $4.4 million, or $0.11 per diluted share, in the prior year period.

Published: 28 January 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Abiomed Inc ( ABMD )

ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients with Metabolic Syndrome and Associated Type 2 Diabetes

- Clinical Trial Application ("CTA") clearance received from Health Canada - Enrollment of patients commencing in Q1 2015

LAVAL, QUEBEC--(Jan 26, 2015) - ProMetic Life Sciences Inc. (PLI.TO)(PFSCF), ("ProMetic" or the "Corporation") reported today that its orally active lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from metabolic syndrome and resulting Type 2 diabetes, following the CTA clearance by Health Canada. Metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL ("good") cholesterol, elevated blood pressure, and elevated blood glucose.

Published: 26 January 2015
Written by Editor
TSX   Up on News   Project Update  
Read more: ProMetic Life Sciences Inc ( PLI )

Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate

Represents Major Step in Company's Preparations to Commence Upcoming Pivotal Phase 3 Trial in Mid-2015

NEW YORK, NY--(Marketwired - January 26, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase 3 trial in mid-2015. The goal of the pre-IND meeting is to finalize preparations for the final stages of its Iomab-B drug candidate development. The initial indication for Iomab-B is conditioning for bone marrow transplant in older relapsed and refractory acute myeloid leukemia (AML) patients, for which there are no FDA approved therapies.

Published: 26 January 2015
Written by Editor
AMEX   Up on News   Project Update  
Read more: Actinium Pharmaceuticals Inc ( ATNM )
  1. Heat Biologics Inc ( HTBX )
  2. Array BioPharma Inc ( ARRY )
  3. Egalet Corporation ( EGLT )
  4. Theralase Technologies Inc ( TLT )
  5. CorMedix Inc ( CRMD )